title: A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
authors.affiliation: a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
authors.forename: Annette E
authors.initials: AE
authors.lastname: Hay
authors.affiliation: b Department of Biology , University of New Brunswick , Saint John , NB , Canada .
authors.forename: Alli
authors.initials: A
authors.lastname: Murugesan
authors.affiliation: c Department of Medicine , Dalhousie University , Saint John , NB , Canada .
authors.forename: Ashley M
authors.initials: AM
authors.lastname: DiPasquale
authors.affiliation: d Juravinski Cancer Centre , Hamilton , ON , Canada .
authors.forename: Tom
authors.initials: T
authors.lastname: Kouroukis
authors.affiliation: e Department of Medicine, Division of Hematology , University of Alberta , Edmonton , AB , Canada .
authors.forename: Irwindeep
authors.initials: I
authors.lastname: Sandhu
authors.affiliation: f Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada .
authors.forename: Vishal
authors.initials: V
authors.lastname: Kukreti
authors.affiliation: g Division of Hematology and Hematologic Malignancies , University of Calgary , Calgary , AB , Canada .
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis
authors.affiliation: g Division of Hematology and Hematologic Malignancies , University of Calgary , Calgary , AB , Canada .
authors.forename: Johan
authors.initials: J
authors.lastname: Lategan
authors.affiliation: f Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada .
authors.forename: Donna E
authors.initials: DE
authors.lastname: Reece
authors.affiliation: h Astex Pharmaceuticals, Inc. , Dublin , CA , USA , and.
authors.forename: John F
authors.initials: JF
authors.lastname: Lyons
authors.affiliation: a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
authors.forename: Joana
authors.initials: J
authors.lastname: Sederias
authors.affiliation: a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
authors.forename: Hao
authors.initials: H
authors.lastname: Xu
authors.affiliation: a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
authors.forename: Jean
authors.initials: J
authors.lastname: Powers
authors.affiliation: a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
authors.forename: Lesley K
authors.initials: LK
authors.lastname: Seymour
authors.affiliation: b Department of Biology , University of New Brunswick , Saint John , NB , Canada .|i Department of Oncology, Saint John Regional Hospital and Department of Medicine , Dalhousie University , Saint John , NB , Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Reiman
mesh_terms: D064127:Aurora Kinases / Q000037:antagonists & inhibitors; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D017211:Treatment Failure; D016896:Treatment Outcome; D014508:Urea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C535237:1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea; D001562:Benzimidazoles; D047428:Protein Kinase Inhibitors; D014508:Urea; D064127:Aurora Kinases